Skip to main content
Free research Free research Free target review with research home and workspace preview
Quick search ChEMBL 36
Loading Target Snapshot...
Querying ChEMBL database. This may take a few seconds.
Target Snapshot

CHEMBL4478 Target Snapshot

Voltage-dependent N-type calcium channel subunit alpha-1B · SINGLE PROTEIN · Homo sapiens

Back to Search Search this target Browse approvals Evidence Card
801Compounds
110Assays
13Approved Drugs
822.0Activities
Free Research Context

Research home keeps recent targets

This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.

Research home Demo workspace
Navigation

Switch target

Move to another high-traffic target or paste a specific ChEMBL target ID.

Broader Open DB context

Frame the target before identity details

Structured disease, protein, and project context should read before the lower-level identity rail.

As of 2026-09-13

Voltage-dependent N-type calcium channel subunit alpha-1B shows approved-linked disease relevance led by pain. 5 more disease programs remain visible in the same review block. 3 linked drugs keep the current disease frame grounded. Protein identity stays anchored to UniProt Q00975. Start with pain, then reuse UniProt Q00975 as the stable protein anchor across project notes and exports.

Review focus
Review-ready target frame

Start with pain, then reuse UniProt Q00975 as the stable protein anchor across project notes and exports.

ChEMBL component mapping + Open Targets-ready proxy + ChEMBL 36 via Core Engine 2026-09-13 3 linked drugs
Open source guide
Disease program
pain

Voltage-dependent N-type calcium channel subunit alpha-1B shows approved-linked disease relevance led by pain. 5 more disease programs remain visible in the same review block. 3 linked drugs remain visible in the same block.

Start review with pain because it currently carries approved-linked support. Linked drugs include RALFINAMIDE, ZICONOTIDE, ZICONOTIDE ACETATE. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Disease source · ChEMBL drug mechanism + indication proxy
Approved-linked Open Targets-ready proxy 3 linked drugs
Open disease block
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Voltage-dependent N-type calcium channel subunit alpha-1B as ChEMBL target CHEMBL4478, mapped to UniProt Q00975. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Voltage-dependent N-type calcium channel subunit alpha-1B
SINGLE PROTEIN · Homo sapiens
As of 2026-09-13
ChEMBL target ID
CHEMBL4478
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-13
www.ebi.ac.uk
UniProt accession
Q00975
Voltage-dependent N-type calcium channel subunit alpha-1B
UniProt accession via ChEMBL component mapping As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-13
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Source Guidance

Start with the right source

Choose the first block or source based on the question you are trying to answer.

Need stable target naming and protein identity?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Start here when your first question is whether Voltage-dependent N-type calcium channel subunit alpha-1B is the right protein anchor across sources, using UniProt Q00975 as the stable mapping.

Jump to Protein Context
Need disease fit before discussing compounds?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use this block first when you need to confirm why pain is currently framed as approved-linked support. It currently carries 3 linked drugs in the same disease frame.

Jump to Disease Context
Need a meeting-ready explanation of why this target matters?
Evidence Card
Review-ready rationale with source-aware context

Open the one-page evidence card when you want the rationale, activity base, and attribution together.

Open Review-ready Card
Overview

Basic Information

Verify identity, organism, and the fastest next research jumps from the same page.

Preferred NameVoltage-dependent N-type calcium channel subunit alpha-1B
Target TypeSINGLE PROTEIN
OrganismHomo sapiens
UniProtQ00975
ChEMBL ↗ UniProt ↗ NCBI Protein ↗

Next Actions

SearchRun a focused querySearch the database using this target name as the starting context. ApprovalsCheck approved moleculesSee which approved drugs connect back to this target and its surrounding signal space. FeedScan papers & updatesStay in the project thread while checking recent papers and platform updates.
UniProt Context

UniProt Target Context

Reviewable protein naming and mapping context for this target snapshot.

Protein LabelVoltage-dependent N-type calcium channel subunit alpha-1B
UniProt AccessionQ00975
Component TypeProtein
Sequence Length2339 aa

Voltage-dependent N-type calcium channel subunit alpha-1B

Source · UniProt accession via ChEMBL component mapping
UniProt Context ↗
Review Cue

How to read this target

Review this target as Voltage-dependent N-type calcium channel subunit alpha-1B, mapped to UniProt Q00975. Sequence length is 2339 aa.

Mapped IDQ00975
Review nameVoltage-dependent N-type calcium channel subunit alpha-1B
OrganismHomo sapiens
Disease Relevance

Disease Relevance & Evidence Level

Open Targets-ready disease context using the current target-indication evidence contract.

Approved-linked Open Targets-ready proxy

Voltage-dependent N-type calcium channel subunit alpha-1B shows approved-linked disease relevance led by pain. 5 more disease programs remain visible in the same review block.

Approved-linked Approved
pain
3 linked drugs · 3 direct · 3 efficacy
Linked drugRALFINAMIDE
Linked drugZICONOTIDE
Linked drugZICONOTIDE ACETATE
Approved-linked Approved
Bilateral tonic-clonic seizure
1 linked drug · 1 direct · 1 efficacy
Linked drugLEVETIRACETAM
Approved-linked Approved
epilepsy
1 linked drug · 1 direct · 1 efficacy
Linked drugLEVETIRACETAM
Approved-linked Approved
epilepsy with generalized tonic-clonic seizures
1 linked drug · 1 direct · 1 efficacy
Linked drugLEVETIRACETAM
Approved-linked Approved
Fever
1 linked drug · 1 direct · 1 efficacy
Linked drugZICONOTIDE
Approved-linked Approved
Focal-onset seizure
1 linked drug · 1 direct · 1 efficacy
Linked drugLEVETIRACETAM
Source · ChEMBL drug mechanism + indication proxy
ChEMBL target record ↗
Review Cue

How to read disease relevance

Start review with pain because it currently carries approved-linked support. Linked drugs include RALFINAMIDE, ZICONOTIDE, ZICONOTIDE ACETATE. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Lead diseasepain
Strongest levelApproved-linked
Block modeOpen Targets-ready proxy
Clinical Profile

Clinical Phase Distribution

13
Approved
2
Phase III
4
Phase II
Assay Mix

Activity Type Distribution

IC50774.0
KI11.0
EC5037.0
Lead Set

Top Inhibitors (by pChEMBL)

ChEMBL IDpChEMBLTypeValue (nM)Phase
CHEMBL4279774 9.0 IC50 1.0 Preclinical
CHEMBL4288564 9.0 IC50 1.0 Preclinical
CHEMBL4292697 9.0 IC50 1.0 Preclinical
CHEMBL4290426 8.7 IC50 2.0 Preclinical
CHEMBL4282095 8.7 IC50 2.0 Preclinical
CHEMBL4289288 8.7 IC50 2.0 Preclinical
CHEMBL5571780 8.52 IC50 3.0 Preclinical
CHEMBL4293756 8.52 IC50 3.0 Preclinical
CHEMBL4278633 8.52 IC50 3.0 Preclinical
CHEMBL5570016 8.34 IC50 4.6 Preclinical
Distribution

pChEMBL Value Distribution

86
5.0
108
5.5
156
6.0
45
6.5
22
7.0
13
7.5
6
8.0
6
8.5
3
9.0
0
9.5
pChEMBL
Approved Drugs

Approved Drugs

ZICONOTIDE
CHEMBL4594214
Approved 2004
Properties Compare Identifier
MIBEFRADIL
CHEMBL45816
Approved 1997
Properties Compare Identifier
Assay Landscape

Assay Landscape

111
Total Assays
383
Tested Compounds
2
Assay Types
Binding — 88 assays, 383 compounds
BAO Format Assays Compounds Avg pChEMBL
cell-based format 48 315 5.8
single protein format 32 41 5.9
assay format 8 27 5.6
Functional — 23 assays, 139 compounds
BAO Format Assays Compounds Avg pChEMBL
cell-based format 15 71 5.6
assay format 7 68 6.1
organism-based format 1 0 —

Confidence Score Distribution

Source · ChEMBL 36 via Core Engine